Chemokines

TheScientificWorldJournal

Volumn 7, Issue , 2007, Pages 224-232

  Horuk, Richard ^a  

^a BAYER AG   (Germany)

Author keywords

Antagonist; Autoimmunity; Chemokine; Endometriosis; GPCR; Multiple myeloma

Indexed keywords

APLAVIROC; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; GSK 873140; LAMIVUDINE PLUS ZIDOVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; RANTES; RITONAVIR; SCH C; UNCLASSIFIED DRUG; VICRIVIROC;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; BONE CELL; CELL DESTRUCTION; CLINICAL TRIAL; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENDOMETRIOSIS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; INFLAMMATION; LIVER TOXICITY; LIVER TRANSPLANTATION; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QT PROLONGATION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CHEMOKINES; HUMANS; IMMUNOLOGIC FACTORS; MODELS, IMMUNOLOGICAL; RECEPTORS, CHEMOKINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33847167606     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2007.6     Document Type: Review

References (37)

1. Baggiolini, M. (1998) Chemokines and leukocyte traffic. Nature 392, 565-568.
2. Horuk, R. (2001) Chemokine receptors. Growth Factor Rev. 12, 313-335.
3. Murphy, P.M. (1994) Molecular piracy of chemokine receptors by herpesviruses. Infect. Agents Dis. 3, 137-154.
4. Horuk, R., Chitnis, C.E., Darbonne, W.C., Colby, T.J., Rybicki, A., Hadley, T.J., and Miller, L.H. (1993) A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 261, 1182-1184.
5. Fredriksson, R. and Schioth, H.B. (2005) The repertoire of g-protein-coupled receptors in fully sequenced genomes. Mol. Pharmacol. 67, 1414-1425.
6. Parry, C.M., Simas, J.P., Smith, V.P., Stewart, C.A., Minson, A.C., Efstathiou, S., and Alcami, A. (2000) A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J. Exp. Med. 191, 573-578.
7. Hesselgesser, J. and Horuk, R. (1999) Chemokine and chemokine receptor expression in the central nervous system. J. Neurovirol. 5, 13-26.
8. Tournamille, C., Colin, Y., Cartron, J.P., and Le Van Kim, C. (1995) Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat. Genet. 10, 224-228.
9. Liu, R., Paxton, W.A., Choe, S., Ceradini, D., Martin, S.R., Horuk, R., MacDonald, M.E., Stuhlmann, H., Koup, R.A., and Landau, N.R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377.
10. Horuk, R. (1994) The interleukin-8-receptor family: from chemokines to malaria. Immunol. Today 15, 169-174.
11. Bennetts, B.H., Teutsch, S.M., Buhler, M.M., Heard, R.N., and Stewart, G.J. (1997) The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol. 58, 52-59.
12. Barcellos, L.F., Schito, A.M., Rimmler, J.B., Vittinghoff, E., Shih, A., Lincoln, R., Callier, S., Elkins, M.K., Goodkin, D.E., Haines, J.L., Pericak-Vance, M.A., Hauser, S.L., and Oksenberg, J.R. (2000) CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51, 281-288.
13. Gade-Andavolu, R., Comings, D.E., MacMurray, J., Rostamkhani, M., Cheng, L.S., Tourtellotte, W.W., and Cone, L.A. (2004) Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet. Med. 6, 126-131.
14. Schreiber, K., Otura, A.B., Ryder, L.P., Madsen, H.O., Jorgensen, O.S., Svejgaard, A., and Sorensen, P.S. (2002) Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1* 1501, CCR5 deletion mutation, apolipoprotein E). Mult. Scler. 8, 295-298.
15. Haase, C.G., Schmidt, S., and Faustmann, P.M. (2002) Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci. Lett. 330, 293-295.
16. Sellebjerg, F., Madsen, H.O., Jensen, C.V., Jensen, J., and Garred, P. (2000) CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102, 98-106.
17. Anderson, K. (1999) Advances in the biology of multiple myeloma: therapeutic applications. Semin. Oncol. 26, 10-22.
18. Anderson, K.C., Shaughnessy, J.D., Jr., Barlogie, B., Harousseau, J.L., and Roodman, G.D. (2002) Multiple myeloma. Hematology 214-240.
19. Choi, S.J., Cruz, J.C., Craig, F., Chung, H., Devlin, R.D., Roodman, G.D., and Alsina, M. (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96, 671-675.
20. Choi, S.J., Oba, Y., Gazitt, Y., Alsina, M., Cruz, J., Anderson, J., and Roodman, G.D. (2001) Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J. Clin. Invest. 108, 1833-1841.
21. Moller, C., Stromberg, T., Juremalm, M., Nilsson, K., and Nilsson, G. (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17, 203-210.
22. Hornung, D., Ryan, I.P., Chao, V.A., Vigne, J.L., Schriock, E.D., and Taylor, R.N. (1997) Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J. Clin. Endocrinol. Metab. 82, 1621-1628.
23. Antinolo, G., Fernandez, R.M., Noval, J.A., Molini, J.L., and Borrego, S. (2004) Analysis of the involvement of CCR5-Delta32 and CCR2-V64I variants in the development of endometriosis. Mol. Hum. Reprod. 10, 155-157.
24. Altman, G.B., Gown, A.M., Luchtel, D.L., and Baker, C. (1999) RANTES production by cultured primate endometrial epithelial cells. Am. J. Reprod. Immunol. 42, 168-174.
25. Hornung, D., Klingel, K., Dohrn, K., Kandolf, R., Wallwiener, D., and Taylor, R.N. (2001) Regulated on activation, normal T-cell-expressed and -secreted mRNA expression in normal endometrium and endometriotic implants: assessment of autocrine/paracrine regulation by in situ hybridization. Am. J. Pathol. 158, 1949-1954.
26. Zhao, D., Lebovic, D.I., and Taylor, R.N. (2002) Long-term progestin treatment inhibits RANTES (regulated on activation, normal T cell expressed and secreted) gene expression in human endometrial stromal cells. J. Clin. Endocrinol. Metab. 87, 2514-2519.
27. Cocchi, F., DeVico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, R.C., and Lusso, P. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells. Science 270, 1811-1815.
28. Feng, Y., Broder, C.C., Kennedy, P.E., and Berger, E.A. (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.
29. Doms, R.W. (2004) Unwelcome guests with master keys: how HIV enters cells and how it can be stopped. Top. HIV Med. 12, 100-103.
30. Fatkenheuer, G., Pozniak, A.L., Johnson, M.A., Plettenberg, A., Staszewski, S., Hoepelman, A.I., Saag, M.S., Goebel, F.D., Rockstroh, J.K., Dezube, B.J., Jenkins, T.M., Medhurst, C., Sullivan, J.F., Ridgway, C., Abel, S., James, I.T., Youle, M., and van der Ryst, E. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11, 1170-1172.
31. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., and Perros, M. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732.
32. Reyes, G. (2001) Development of CCR5 antagonists as a new class of anti-HIV therapeutic. Abstract L11. In 8th Conference on Retroviruses and Opportunistic Infections, Chicago.
33. Schurmann, D., Rouzier, R., Nougarede, R., Reynes, J., Fatkenheuer, G., Raffi, F., Michelet, C., Tarral, A., Hoffmann, C., Kiunke, J., Sprenger, H., vanLier, J., Sansone, A., Jackson, M., and Laughlin, M. (2003) SCH D: antiviral activity of a CCR5 receptor antagonist. In 11th Conference on Retroviruses and Opportunistic Infections, San Francisco.
34. Strizki, J.M. (2005) Properties of in vitro generated HIV-1 variants resistant to the CCR5 antagonists SCH 351125 and SCH 417690. Abstr. 59 (poster). 14th International HIV Drug Resistance Workshop IC Report: Basic Principles and Clinical Implications. June 7-11, 2005, Québec City, Québec, Canada.
35. Maeda, K., Nakata, H., Koh, Y., Miyakawa, T., Ogata, H., Takaoka, Y., Shibayama, S., Sagawa, K., Fukushima, D., Moravek, J., Koyanagi, Y., and Mitsuya, H. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78, 8654-8662.
36. Demarest, J., Adkison, K., Sparks, S., Shachoy-Clark, A., Schell, K., Reddy, S., Fang, L., O'Mara, K., Shibayama, S., and Piscitelli, S. (2003) Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 receptor antagonist, in healthy subjects. In 11th Conference on Retroviruses and Opportunistic Infections, San Francisco.
37. Lalezari, J., Thompson, M., Kumar, P., Piliero, P., Davey, R., Patterson, K., Shachoy-Clark, A., Adkison, K., Demarest, J., Lou, Y., Berrey, M., and Piscitelli, S. (2005) Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19, 1443-1448.